Melanotan 1 (afamelanotide): what the research shows

  • By Reed Calder
  • Last reviewed Nov 12, 2026
  • 32 studies and official documents checked

In short

Melanotan 1 is afamelanotide, a lab-made copy of the hormone that darkens skin. The same peptide is the active ingredient of Scenesse, an FDA-approved implant for adults with erythropoietic protoporphyria (EPP), a rare disorder that makes sunlight painful. In the U.S. trial of the implant, patients spent a median 69.4 hours in direct sun without pain, against 40.8 on placebo. Injected for tanning, it darkened the skin of healthy volunteers in five studies of 3 to 77 people, and in one placebo-controlled trial of 28 men nobody on placebo darkened. No study tested the powders sold online, we found no lab analysis of those vials, and the longest course of injections for tanning was 3 months. The approved implant carries a label that calls for a full-body skin exam twice a year.

EvidenceCellAnimalHuman

Melanotan 1 is sold online as an injectable powder for tanning, and the molecule inside the approved implant is the same one. This page covers what it is, what the human studies found for tanning, for EPP and for skin conditions, what is known about moles and skin checks, how it differs from Melanotan 2, and where it stands legally.

Names and forms you’ll see

The names on Melanotan 1 products
Name What it is Studied in people?
Melanotan 1, Melanotan I, MT-1, MT-I The research and sales name for a straight chain of 13 amino acids copied from alpha-MSH with two amino acids changed (Böhm et al., 2025) Yes
Afamelanotide The international nonproprietary name for the same peptide (FDA GSRS) Same as Melanotan 1
Scenesse The brand name of the FDA-approved implant that contains afamelanotide (FDA label, 2024) Yes: approved for one rare disorder
[Nle4, D-Phe7]-alpha-MSH, NDP-MSH The chemical names used in older papers; the 1991 to 2006 trials call the peptide “melanotan” (Levine et al., 1991; Fitzgerald et al., 2006) Same as Melanotan 1
CUV1647 The development code of the company that makes Scenesse, listed among the peptide’s names (FDA GSRS) Same as Melanotan 1
“Melanotan” alone Can mean Melanotan 1 or the different, ring-shaped Melanotan 2 Unclear

CAS numbers

A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The base peptide and the acetate form in the implant have different registry numbers.

Melanotan 1 CAS numbers
Form CAS number Registry record
Melanotan I (afamelanotide) 75921-69-6 FDA GSRS
Afamelanotide acetate (the form in the Scenesse implant) 1566590-77-9 FDA GSRS

What Melanotan 1 is

Your body makes alpha-MSH, a hormone that switches on a receptor called MC1R on skin pigment cells. They respond by making eumelanin, the dark pigment (Böhm et al., 2025). Melanotan 1 is a copy of that hormone with two amino acids changed, which made it more active and more stable than the natural hormone. It was first made in 1980 (Minder et al., 2017).

It binds mainly to MC1R, then to MC3R, MC4R and MC5R in falling order of strength (Böhm et al., 2025). The FDA label gives its structure and says it “binds predominantly to MC1-R” (FDA label, 2024).

From the implant, blood levels peak at about 36 hours and the apparent half-life is about 15 hours (FDA label, 2024). After an injection under the skin, three men took it up fully and cleared it with a half-life of 0.8 to 1.7 hours (Ugwu et al., 1997).

Melanotan 2 is a different, ring-shaped peptide, and PT-141 came out of the same line of work (Hadley and Dorr, 2006).

What has been studied

Injections for tanning in healthy volunteers

  • 28 men, placebo-controlled. Healthy white men received 10 injections of the peptide or saline over 12 days and used a high-potency sunscreen throughout. Skin darkened on the peptide in both easy-tanning and poor-tanning skin types, and not at all on saline. Darkening peaked 1 to 3 weeks after the last dose, and the men were followed for 7 weeks (Levine et al., 1991).
  • 3 men, three routes. Doses were 0.16 milligrams per kilogram into a vein and by mouth, and 0.08 to 0.21 under the skin, ten doses over 2 weeks. Under the skin it was fully absorbed and tanned the forehead, arms and neck; nothing was detectable after the oral dose. Side effects were occasional stomach upset and facial flushing. Tanning peaked at 1 week and was still there 3 weeks after the last dose (Ugwu et al., 1997).
  • 7 volunteers. Ten daily injections (Monday to Friday for 2 weeks) at 0.16 milligrams per kilogram a day tanned 3 of 8 body sites. Eumelanin rose 98% in forearm skin and 49% in the forehead of the 3 people sampled there, and the red-yellow pigment did not change (Dorr et al., 2000).
  • 65 volunteers, placebo-controlled. Three 10-day courses over 3 months at 0.16 milligrams per kilogram under the skin of the abdomen. Skin pigment rose 41% in people whose skin burns easily and 12% in people whose skin burns less easily. In the first group, sunburn cells after UV exposure fell by more than half and a marker of DNA damage (thymine dimers) fell 59% (Barnetson et al., 2006).
  • 77 people, gene variants. Pigment rose more than on placebo, and more in people carrying MC1R variant alleles, the red-hair genes (Fitzgerald et al., 2006).
  • Not by mouth or skin. A review of these studies says neither oral nor transdermal dosing gave measurable blood levels (Minder et al., 2017).

Together these show that injected Melanotan 1 darkens skin in controlled trials. None tested the powders sold online, and none ran longer than 3 months.

The implant for EPP

  • 5 patients, open-label. Two 20 milligram implants 60 days apart; sunlight tolerance rose by up to 24 times, and the authors asked for a larger trial (Harms et al., 2009).
  • Two placebo-controlled trials. Implants of 16 milligrams every 60 days. In the U.S. trial, 94 patients had three implants over 180 days and the median pain-free time in direct sunlight was 69.4 hours against 40.8 on placebo (P = 0.04). In the EU trial, 74 patients had five implants over 270 days: 6.0 hours against 0.8 (P = 0.005), and 77 phototoxic reactions against 146. Quality of life improved in both, and the trials were funded by the maker and others (Langendonk et al., 2015).
  • The FDA’s count of the same trials. The label lists 93 subjects in the U.S. trial with medians of 64.1 and 40.5 hours, and 74 in the EU trial with 6.0 and 0.75 hours (FDA label, 2024). The numbers differ from the journal’s because the label recounts them.
  • 8 years of follow-up. 115 patients at two centres had 1,023 implants. Quality-of-life scores rose from 31% to 74% of the maximum and stayed there; adverse events were minor, mostly nausea. 23% stopped, mostly for reasons such as pregnancy or financial limits (Biolcati et al., 2015).
  • Routine care. In 117 patients followed a median 2 years, 98% continued; time outside rose 6.1 hours a week and quality of life 14%. Reactions were less painful but not fewer or shorter (Wensink et al., 2020).
  • Blood and liver markers. In a retrospective look at 38 Swiss patients, protoporphyrin fell from 21.39 to 16.83 micromoles per litre (Minder et al., 2021). This was not a trial.

Vitiligo and other skin conditions

  • Vitiligo, randomized. 55 adults with vitiligo on 15 to 50% of the body had light therapy alone or with a 16 milligram implant monthly for 4 months. At day 168, repigmentation was 48.64% with the implant against 33.26% without, and faster on the face and arms. The benefit was clearer in darker skin types IV to VI (Lim et al., 2015).
  • A larger vitiligo trial. A phase 3 trial of 200 patients, comparing the implant plus light therapy with light therapy alone, is registered as active but not recruiting, with no results posted (ClinicalTrials.gov).
  • Small open-label studies, no control group. In 5 patients with sun-triggered hives, one implant raised skin pigment by day 7 and weal area fell at day 60 (Haylett et al., 2011). In 3 patients with acne, lesion counts fell at day 56 (Böhm et al., 2014). In 6 patients with acute stroke, implants were given on days 0 and 1, and again on days 7 and 8 for some; one patient died of a recurrent stroke judged unrelated to the drug (Stanislaus et al., 2023).

Moles, skin checks and the long run

  • What the label says. The implant can darken existing moles and freckles, and the label recommends a full-body skin exam twice a year (FDA label, 2024).
  • Moles under the dermoscope. In 15 EPP patients with 103 moles, changes seen under the dermoscope after two implants reversed by 12 months, none suggested cancer and no new moles appeared (Arisi et al., 2021).
  • Melanoma. A 2025 review reports more than 1,000 people exposed to afamelanotide and no melanoma events, and says activating MC1R does not prevent melanoma (Böhm et al., 2025). The review was paid for by Rhythm Pharmaceuticals, which makes a different melanocortin drug.
  • Antibodies. No antibodies to the drug were found in 23 of 26 patients treated for up to 6 years; 3 had reactivity before treatment that did not change (Lengweiler et al., 2015).
  • Late effects. A review reports none in volunteers 25 years after the first exposure (Minder et al., 2017).

EvidenceCellAnimalHuman

The usual claims, checked

Common Melanotan 1 claims vs the studies
Claim Verdict What the studies found
It tans you without sun Supported In placebo-controlled injection trials skin darkened and peaked 1 to 3 weeks after the last dose (Levine et al., 1991; Barnetson et al., 2006). No trial tested the powders sold online
There is no controlled evidence it tans Contradicted There is: a placebo-controlled trial of 28 men and another of 65 volunteers (Levine et al., 1991; Barnetson et al., 2006). What is missing is a test of the online product and any study past 3 months
It protects against sunburn and skin cancer Mixed In volunteers who burn easily, sunburn cells and a DNA-damage marker fell (Barnetson et al., 2006). A 2025 review says the extra pigment does not prevent melanoma and skin exams stay important (Böhm et al., 2025)
It is an FDA-approved drug Mixed As the Scenesse implant, for adults with EPP, placed by a trained professional (FDA label, 2024). A powder sold online is not Scenesse
It has no side effects Contradicted In the approved-drug trials, implant-site reactions were 21% against 10% on vehicle and nausea 19% against 14% (FDA label, 2024). Injections caused occasional stomach upset and flushing (Ugwu et al., 1997)
It works by mouth, as a nasal spray or on the skin Contradicted Nothing was detectable after an oral dose (Ugwu et al., 1997), and a review says neither oral nor transdermal dosing gave measurable levels (Minder et al., 2017). We found no nasal study
The tan lasts for months Untested Tanning was still present 3 weeks after the last dose in one study, and the longest follow-up was 7 weeks (Ugwu et al., 1997; Levine et al., 1991)
It causes melanoma Untested The melanoma case reports we read name Melanotan 2 (see Melanotan 2); we found none naming Melanotan 1 alone. A review lumps both together and calls the evidence lacking (Habbema et al., 2017)
It helps vitiligo, acne or stroke Mixed One randomized vitiligo trial found more repigmentation with light therapy (48.64% vs 33.26%) (Lim et al., 2015). Acne and stroke were tried in 3 and 6 people with no control group (Böhm et al., 2014; Stanislaus et al., 2023)
A lab certificate proves the vial is the approved drug Contradicted A certificate shows what one lot held on one test. Scenesse is a sterile implant made and labeled under FDA rules (FDA label, 2024). We found no published analysis of Melanotan 1 vials; for Melanotan 2, vial tests found less peptide than labeled (see Melanotan 2)

Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.

Melanotan 1 and Melanotan 2

Melanotan 1 compared with Melanotan 2
Melanotan 1 (afamelanotide) Melanotan 2
Shape A straight chain of 13 amino acids; mass 1,647 (PubChem) A ring of 7 amino acids; mass 1,024 (PubChem)
Receptors Mainly MC1R in pigment cells, then MC3R, MC4R and MC5R (Böhm et al., 2025) Non-selective; effects include fatigue, loss of appetite and erections (Böhm et al., 2025)
Tested for Tanning, EPP, vitiligo (Levine et al., 1991; Langendonk et al., 2015; Lim et al., 2015) Erectile dysfunction (Hadley and Dorr, 2006)
Tanning evidence in people 5 injection studies in 3 to 77 volunteers, three placebo-controlled (Levine et al., 1991; Barnetson et al., 2006; Fitzgerald et al., 2006) One 3-man study (see Melanotan 2)
Approval FDA-approved as Scenesse, an implant, for EPP (FDA, 2019) Not approved for any use (Böhm et al., 2025)
Skin checks The label recommends a full-body skin exam twice a year (FDA label, 2024) No label
Vial analyses None found Several; see Melanotan 2

Side effects and safety

  • In the approved-drug trials. Among 244 adults with EPP (125 on the implant, 119 on vehicle), the common reactions were implant-site reactions (21% vs 10%), nausea (19% vs 14%), throat pain (7% vs 5%), cough (6% vs 3%), fatigue (6% vs 3%), skin darkening (4% vs 0%), dizziness (4% vs 3%) and a mole reported (4% vs 2%) (FDA label, 2024).
  • After approval. Serious allergic reactions, including anaphylaxis, have been reported (FDA label, 2024).
  • Injected for tanning. Volunteers had occasional stomach upset and facial flushing (Ugwu et al., 1997).
  • Moles. The implant can darken moles and freckles, which is why the label calls for skin exams twice a year (FDA label, 2024).
  • Pregnancy. The label says there are no data on use in pregnant women, and it has no data on breast milk (FDA label, 2024).
  • Unregulated use. A review links unregulated Melanotan 1 and 2 use to changes in moles and says the risks include dose and preparation questions (Habbema et al., 2017). A Dutch dental review describes darkening of the mouth’s soft tissues and says adverse effects and overdoses of afamelanotide have been reported to Dutch health agencies, without giving numbers (de Baat et al., 2020). Needle sharing and impure product are further risks (Langan et al., 2010).
  • Case reports. A 2026 review lists muscle breakdown, kidney damage and priapism after unregulated melanotan use (Resnick et al., 2026). The case reports we read are for Melanotan 2, covered on its page; none in our search named Melanotan 1 alone.
  • Longest data. 8 years of implants in EPP patients, and no late effects reported in volunteers 25 years after first exposure (Biolcati et al., 2015; Minder et al., 2017).

Legal and approval status

  • Approved in the U.S. for one use. The FDA approved Scenesse on October 8, 2019, to increase pain-free light exposure in adults with a history of phototoxic reactions from EPP. One 16 milligram implant goes under the skin above the hip bone every 2 months, placed by a trained professional (FDA, 2019; Drugs@FDA via openFDA; FDA label, 2024).
  • Approved in the EU for one use. The European Commission authorised it on December 22, 2014 to prevent phototoxicity in adults with EPP, under “exceptional circumstances.” Only trained specialist doctors in recognised centres prescribe it (EMA).
  • Not approved for tanning. Neither agency approved it for that use. Powders sold online are not Scenesse.
  • Not on the FDA’s compounding lists. The FDA’s safety-risk page names Melanotan II but not Melanotan 1 or afamelanotide, and its May 2026 compounding categories have no entry for either (FDA, 2026; FDA list, May 2026).
  • Registered studies. ClinicalTrials.gov lists 23 afamelanotide studies, all sponsored by the maker (ClinicalTrials.gov search).
  • Sport. The World Anti-Doping Agency’s 2026 list names neither Melanotan nor afamelanotide, and its S0 class covers only drugs no government has approved, while afamelanotide is approved in the U.S. and EU (WADA, 2026). We found no WADA statement on it.
  • Not in the October 2026 HHS policy. That temporary policy covers six other peptides (Reuters, 2026).
  • “Research use only” products aren’t approved for use in people.

What to look for if you research it

We don’t name or link sellers. These checks come from the studies and the label:

  • Which melanotan? Melanotan 1 is CAS 75921-69-6 and Melanotan 2 is CAS 121062-08-6; they are different peptides (FDA GSRS; FDA GSRS).
  • Not the approved product. Scenesse is a sterile rod about 1.7 cm long, 16 milligrams, made with a biodegradable polymer, and stored refrigerated (FDA label, 2024). A powder in a vial is a different product.
  • Whose study? The tanning trials used 0.16 milligrams per kilogram for 10 days, and the implant label uses 16 milligrams every 2 months. They are different regimens, and neither tested a powder from a website (Barnetson et al., 2006; FDA label, 2024).
  • What a lab report shows. It tells you what one lot held; it does not show sterility, the sequence of every molecule or a safe dose. We found no published tests of Melanotan 1 vials.
  • Skin checks. The one approved product comes with twice-yearly skin exams (FDA label, 2024).

Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite. For related compounds, see sexual health and hormones.

Trials under way

Already under way: 1 active, not recruiting.

What’s still unknown

  • Whether the powders sold online contain the peptide, how much, and whether they are sterile: we found no published tests.
  • Safety and tanning past 3 months of injections: no trial went longer.
  • Whether self-injected Melanotan 1 changes melanoma risk: the reports we read are for Melanotan 2, and no study follows users.
  • Whether it works by nasal spray, which no study tested.
  • How the vitiligo result holds up: the phase 3 trial has no posted results.

Retracted and flagged studies

A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.

We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention Melanotan 1. We recheck every month. Last checked Nov 12, 2026.

We found no retracted, withdrawn or flagged studies that mention Melanotan 1.

Studies this page relies on

Status of every study cited on this page
Study Published in Status
Levine et al., 1991 JAMA No retraction or concern
Ugwu et al., 1997 Biopharm Drug Dispos No retraction or concern
Dorr et al., 2000 Photochem Photobiol No retraction or concern
Fitzgerald et al., 2006 Peptides No retraction or concern
Hadley and Dorr, 2006 Peptides No retraction or concern
Barnetson et al., 2006 J Invest Dermatol No retraction or concern
Harms et al., 2009 Photochem Photobiol No retraction or concern
Langan et al., 2010 Br J Dermatol No retraction or concern
Haylett et al., 2011 Br J Dermatol No retraction or concern
Böhm et al., 2014 J Eur Acad Dermatol Venereol No retraction or concern
Lim et al., 2015 JAMA Dermatol No retraction or concern
Lengweiler et al., 2015 Skin Pharmacol Physiol No retraction or concern
Biolcati et al., 2015 Br J Dermatol No retraction or concern
Langendonk et al., 2015 N Engl J Med No retraction or concern
Minder et al., 2017 Clin Pharmacokinet No retraction or concern
Habbema et al., 2017 Int J Dermatol No retraction or concern
Wensink et al., 2020 JAMA Dermatol No retraction or concern
de Baat et al., 2020 Ned Tijdschr Tandheelkd No retraction or concern
Arisi et al., 2021 Photochem Photobiol Sci No retraction or concern
Minder et al., 2021 Ther Adv Rare Dis No retraction or concern
Stanislaus et al., 2023 BMC Neurol No retraction or concern
Böhm et al., 2025 J Eur Acad Dermatol Venereol No retraction or concern
Resnick et al., 2026 J Clin Aesthet Dermatol No retraction or concern

Bring your questions to other researchers

Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.

Questions

What is Melanotan 1?

A lab-made peptide of 13 amino acids copied from the hormone alpha-MSH, which switches on pigment cells. The same peptide is the active ingredient in the approved implant Scenesse (Böhm et al., 2025; FDA label, 2024).

Is Melanotan 1 the same as afamelanotide?

Yes. Afamelanotide is its international nonproprietary name (FDA GSRS).

Is Melanotan 1 the same as Scenesse?

The peptide is the same, but Scenesse is a sterile 16 milligram implant placed by a trained professional for EPP. A powder sold online is not Scenesse (FDA label, 2024).

Does Melanotan 1 make you tan?

In placebo-controlled injection trials, yes: skin darkened on the peptide and not on saline (Levine et al., 1991; Barnetson et al., 2006). No trial tested the online powders.

How fast does Melanotan 1 work?

Tanning peaked about 1 week after a course of injections in one study and 1 to 3 weeks after the last dose in another (Ugwu et al., 1997; Levine et al., 1991). Skin pigment rose by day 7 after an implant (Haylett et al., 2011).

How long does a Melanotan 1 tan last?

It was still present 3 weeks after the last dose in 3 men, and one trial followed volunteers for 7 weeks (Ugwu et al., 1997; Levine et al., 1991). We found no longer follow-up.

What are the benefits of Melanotan 1?

In the approved implant, more pain-free time in sunlight for adults with EPP (Langendonk et al., 2015). More repigmentation in vitiligo when used with light therapy (Lim et al., 2015). A tan from injections in volunteers (Levine et al., 1991).

Is Melanotan 1 safe?

The approved implant has a label with a safety table, skin exams twice a year and a warning on allergic reactions (FDA label, 2024). For powders sold online, we found no trial or published vial test, so it is unknown.

What are the side effects of Melanotan 1?

In the label’s trials, implant-site reactions, nausea, throat pain, cough and fatigue; injected volunteers had stomach upset and flushing (FDA label, 2024; Ugwu et al., 1997).

Does Melanotan 1 cause melanoma?

We don’t know. The case reports we read are for Melanotan 2, and a 2025 review reports no melanoma events in more than 1,000 people given afamelanotide, though it was paid for by another drug maker (Böhm et al., 2025; Habbema et al., 2017).

Melanotan 1 vs Melanotan 2: what is the difference?

Melanotan 1 is a straight chain acting mostly on pigment cells; Melanotan 2 is a ring that acts on more receptors and brought on erections and nausea in studies. Only Melanotan 1 has an approved form (Böhm et al., 2025; FDA, 2019). See Melanotan 2.

Is Melanotan 1 safer than Melanotan 2?

We found no trial comparing them. Melanotan 1 has an approved form with a labeled safety record; for both, powders sold online have no safety data. We found no Melanotan 1 vial tests, while Melanotan 2 vials have been tested (FDA label, 2024).

Is Melanotan 1 FDA approved?

Only as Scenesse, for adults with EPP. The FDA approved it on October 8, 2019 (FDA, 2019).

Does Melanotan 1 work by mouth or as a nasal spray?

Nothing was detectable in the blood after an oral dose, and no study tested a nasal spray (Ugwu et al., 1997; Minder et al., 2017).

Does Melanotan 1 help vitiligo?

One randomized trial found more repigmentation with the implant plus light therapy than with light therapy alone, 48.64% vs 33.26% at day 168 (Lim et al., 2015). A phase 3 trial has no results yet (ClinicalTrials.gov).

What is the Melanotan 1 dosage?

The FDA label dose for Scenesse is one 16 milligram implant under the skin every 2 months, placed by a trained professional (FDA label, 2024). Tanning trials injected 0.16 milligrams per kilogram a day for 10 days, with doses of 0.08 to 0.21 in one study, and the 65-volunteer trial gave three 10-day courses over 3 months (Dorr et al., 2000; Ugwu et al., 1997; Barnetson et al., 2006). The vitiligo trial gave 16 milligrams monthly for 4 months (Lim et al., 2015). No study has set a dose for powders bought online, and we don’t give dosing advice.

Sources

  1. Levine N, et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA. 1991;266(19):2730-6. PubMed 1658407
  2. Ugwu SO, et al. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharm Drug Dispos. 1997;18(3):259-69. PubMed 9113347
  3. Dorr RT, et al. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochem Photobiol. 2000;72(4):526-32. PubMed 11045725
  4. Barnetson RS, et al. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol. 2006;126(8):1869-78. PubMed 16763547
  5. Fitzgerald LM, et al. Effect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles. Peptides. 2006;27(2):388-94. PubMed 16293341
  6. Harms JH, et al. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem Photobiol. 2009;85(6):1434-9. PubMed 19656325
  7. Langendonk JG, et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015;373(1):48-59. PubMed 26132941
  8. Biolcati G, et al. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172(6):1601-1612. PubMed 25494545
  9. Wensink D, et al. Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice. JAMA Dermatol. 2020;156(5):570-575. PubMed 32186677
  10. Minder AE, et al. Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study. Ther Adv Rare Dis. 2021;2:26330040211065453. PubMed 37181106
  11. Lengweiler S, et al. Evaluation of the immunogenicity of the synthetic α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ([Nle4-D-Phe7]-α-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies. Skin Pharmacol Physiol. 2015;28(2):103-13. PubMed 25402764
  12. Lim HW, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015;151(1):42-50. PubMed 25230094
  13. Haylett AK, et al. Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-α-MSH. Br J Dermatol. 2011;164(2):407-14. PubMed 20969564
  14. Böhm M, et al. Beneficial effects of the melanocortin analogue Nle4-D-Phe7-α-MSH in acne vulgaris. J Eur Acad Dermatol Venereol. 2014;28(1):108-11. PubMed 22845050
  15. Stanislaus V, et al. A feasibility and safety study of afamelanotide in acute stroke patients - an open label, proof of concept, phase iia clinical trial. BMC Neurol. 2023;23(1):281. PubMed 37496004
  16. Arisi M, et al. Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide. Photochem Photobiol Sci. 2021;20(2):315-320. PubMed 33721252
  17. Böhm M, et al. An overview of benefits and risks of chronic melanocortin-1 receptor activation. J Eur Acad Dermatol Venereol. 2025;39(1):39-51. PubMed 39082868
  18. Habbema L, et al. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017;56(10):975-980. PubMed 28266027
  19. Minder EI, et al. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clin Pharmacokinet. 2017;56(8):815-823. PubMed 28063031
  20. de Baat C, et al. [Medicaments and oral healthcare. Hyperpigmentation of oral soft tissues due to afamelanotide]. Ned Tijdschr Tandheelkd. 2020;127(4):237-243. PubMed 32459219
  21. Langan EA, et al. Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'?. Br J Dermatol. 2010;163(3):451-5. PubMed 20545686
  22. Resnick G, et al. Insights into Tanning Biology and Tanning Products. J Clin Aesthet Dermatol. 2026;19(2):33-42. PubMed 41890775
  23. Hadley ME, et al. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-30. PubMed 16412534
  24. U.S. Food and Drug Administration. Scenesse (afamelanotide) implant prescribing information. NDA 210797; revised August 2024. FDA label
  25. U.S. Food and Drug Administration. Scenesse approval letter, NDA 210797. October 8, 2019. FDA letter
  26. U.S. Food and Drug Administration. Drugs@FDA data via openFDA, searched November 12, 2026: Scenesse implant 16 mg, NDA 210797, original approval October 8, 2019. openFDA search
  27. European Medicines Agency. Scenesse (afamelanotide) European public assessment report page, read November 12, 2026. EMA page
  28. ClinicalTrials.gov. Search for afamelanotide, November 12, 2026: 23 studies. Search; NCT06109649
  29. U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
  30. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. Updated May 14, 2026. FDA document
  31. World Anti-Doping Agency. 2026 Prohibited List, section S0. WADA document
  32. Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
  33. U.S. Food and Drug Administration. Global Substance Registration System: AFAMELANOTIDE (UNII QW68W3J66U). GSRS
  34. U.S. Food and Drug Administration. Global Substance Registration System: AFAMELANOTIDE ACETATE (UNII 1XCC161YKC). GSRS
  35. U.S. Food and Drug Administration. Global Substance Registration System: MELANOTAN II (UNII UPF5CJ93X7). GSRS

Last reviewed Nov 12, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.